Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta‐analysis of randomized controlled trials
Authors' conclusion
Teplizumab increases AUC of C-peptide levels and decreases HbA1c levels and insulin use, without raising serious adverse event risk.
Study context
- Population
- Patients with Stage 3 T1D in randomized controlled trials (RCTs) comparing teplizumab to placebo (PubMed, Embase, Cochrane)
- Participants
- 1,052 patients8 RCTs
- Comparison
- Teplizumab vs placebo
- Teplizumabn = 754
- Outcome
- C-peptide AUC
Pooled result
As reported in the abstract
Teplizumab vs PlaceboMD, nmol/L (95% CI)
6 months
0.10(0.05–0.16)
12 months
0.13(0.06–0.20)
18 months
0.18(0.09–0.27)
24 months
0.16(0.02–0.31)
Further pooled results
| Outcome | MD (%) (95% CI) | |
|---|---|---|
| HbA1cTeplizumabvs Placebo6 months | −0.57 (−1.07 to −0.08) | |
| HbA1cTeplizumabvs Placebo12 months | −0.31 (−0.59 to −0.02) | |
| −1.5−1−0.500.5Difference, % (linear scale) |
| Outcome | MD (U/kg) (95% CI) | |
|---|---|---|
| Insulin requirementsTeplizumabvs Placebo6 months | −0.12 (−0.16 to −0.08) | |
| Insulin requirementsTeplizumabvs Placebo12 months | −0.11 (−0.15 to −0.07) | |
| Insulin requirementsTeplizumabvs Placebo18 months | −0.17 (−0.26 to −0.09) | |
| Insulin requirementsTeplizumabvs Placebo24 months | −0.11 (−0.22 to −0.01) | |
| −0.4−0.200.2Difference, U/kg (linear scale) |
Original publication
Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 11 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →